CD274 and neoplasm: Studies involving pembrolizumab had reported the combined positive score (CPS), defined as the ratio of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) out of the total number of tumor cells × 100 (11, 12, 17, 30, 41).